Viveve Medical (NASDAQ:VIVE) announced its earnings results on Thursday, March 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06), Bloomberg Earnings reports. The firm had revenue of $5.10 million for the quarter, compared to analyst estimates of $5.09 million. Viveve Medical had a negative return on equity of 328.38% and a negative net margin of 241.75%.
NASDAQ:VIVE traded down $0.10 during mid-day trading on Friday, reaching $3.19. 221,663 shares of the company were exchanged, compared to its average volume of 301,358. Viveve Medical has a 12 month low of $3.12 and a 12 month high of $11.16. The company has a quick ratio of 3.16, a current ratio of 3.41 and a debt-to-equity ratio of -11.13. The firm has a market cap of $102.76, a P/E ratio of -1.51 and a beta of -0.49.
An institutional investor recently bought a new position in Viveve Medical stock. State Street Corp bought a new stake in Viveve Medical (NASDAQ:VIVE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 178,606 shares of the company’s stock, valued at approximately $1,282,000. State Street Corp owned about 0.92% of Viveve Medical at the end of the most recent quarter. 40.19% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently issued reports on VIVE shares. ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Northland Securities started coverage on shares of Viveve Medical in a research report on Friday, January 5th. They set an “outperform” rating and a $8.00 target price for the company. Mizuho reiterated a “buy” rating and set a $10.00 target price on shares of Viveve Medical in a research report on Friday, January 5th. Ladenburg Thalmann reiterated a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. Finally, Maxim Group reissued a “buy” rating and set a $11.00 price objective on shares of Viveve Medical in a report on Friday, March 16th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Viveve Medical presently has a consensus rating of “Buy” and a consensus price target of $10.00.
COPYRIGHT VIOLATION NOTICE: “Viveve Medical (NASDAQ:VIVE) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/viveve-medical-vive-announces-quarterly-earnings-results.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.